# Final Portfolio Evidence Pack

## Executive case

ContinuumOS is a hypothetical orchestration overlay for diagnostic closure: result available → clinician acknowledgement → human follow-up direction → referral handoff → next-step confirmation or documented exception. It is not an EHR replacement.

The local prototype demonstrates one approved synthetic tracer with separate human gates for clinical direction, referral routing, receiving response and closure. The portfolio case is supported by its requirements, decision rights, safety controls, test evidence and stated limits.

## Evidence status

| Evidence type | Recorded evidence | What it does not establish |
|---|---|---|
| Design baseline | Sprint 1–5 product, workflow, requirements and architecture artifacts | Real-world need, adoption or outcomes |
| Prototype and controlled test | Sprint 6B clean-session regression, TypeScript lint, 85 Node tests and browser checks | Clinical validation, deployment or live integration |
| Synthetic pilot | Sprint 7: 20 controlled runs of one tracer; all passed; four browser-observed actions took 0.311–0.748 seconds | 20 unique episodes, human task time, SLA, AI quality or production performance |
| Internal Product Owner review | Six documented presentation findings on 28 July 2026; each produced a bounded change and retest in `change_evidence_table.csv` | External reviewer research, clinical validation or evidence of user adoption |
| Competitive approach appendix | Four adjacent approaches compared using official public sources retrieved on 28 July 2026 | Market ranking, competitor weakness, procurement advice or ContinuumOS results |

## Evidence-backed decisions

Internal Product Owner feedback identified that generic roles, technical source wording and invisible handoffs weakened prototype credibility. The approved response added a clearly fictional care network, named synthetic staff and contextual simulated system provenance. A later review identified missing verified patient context, which led to a bounded read-only context dialog that suppresses itself on protected-access failures. A successful confirmation also lacked a concise handoff reference, so a read-only confirmed next-step summary was added after `EVT-16`.

Each change was presentation-only or used approved fixture context. Controller logic, canonical state, human authority, persistence, live integration and AI-safety boundaries did not change. The source, decision, requirement scope and retest for every change are recorded in `change_evidence_table.csv`.

This is internal Product Owner review, not external reviewer research. No external reviewer participation is claimed.

## BA evidence

- Requirements and traceability: Sprint 5 requirements register and RTM, linked to Sprint 6 story and test evidence.
- Process and decision rights: explicit state, owner and next action; clinical direction, referral routing, receiving response and closure remain separate human decisions.
- Risk and governance: Sprint 6 hazard register, defect and release evidence; known limitations are retained rather than converted into readiness claims.
- Change control: Product Owner findings, bounded decisions and retests are recorded in the Sprint 7 change-evidence table.
- Pilot control: `synthetic_pilot_dataset_and_method.md` and `pilot_result_summary.csv` distinguish local scripted runs from operational performance.

## AI PM evidence

AI-01 and AI-02 are source-linked drafts only. They cannot diagnose, acknowledge, select direction, approve, route, accept, reject, confirm or close work. The prototype supports authorised accept, correct with rationale, reject/discard and manual fallback. The current, stale and unavailable fixture evidence is not a deployed-model evaluation.

## Safety decision: wrong patient or encounter attachment

`SAFE-01` treats uncertain linkage as a Critical risk. Prevention is verified Patient, Encounter and event references; detection is reconciliation and exception evidence; recovery preserves the last verified state and routes work to an Identity reconciliation reviewer. The accepted operating cost is visible interruption and manual verification rather than silent attachment. Executed evidence covers synthetic missing-encounter quarantine and recovery only. Real MPI behaviour, error prevalence and harm remain unresolved.

## Current delivery position

Release 0.2 has a Product Owner Conditional Go for structured synthetic review and synthetic workflow evaluation only. Sprint 7 packaging uses internal Product Owner review as its documented change-evidence stream; the planned external structured-review work was explicitly waived for this portfolio case and is not represented as completed research.

The standard Vite build is retained as a managed-workspace output-directory limitation. Lint and 85 Node tests passed, and a runner build to a fresh temporary output directory passed. This does not establish deployment readiness.

## Open evidence needed

External reviewer research, clinical validation, real operational performance, subgroup fairness evaluation, production adversarial security and external-model supplier assurance remain outside the package. A normal local build from a writable checkout remains the next technical environment check.
